¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"lethal gene"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • catabolite (gene) activator protein
    ºÐÇØ´ë»ç»ê¹°(À¯ÀüÀÚ)Ȱ¼º´Ü¹éÁú
  • calcitonin gene-related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • candidate gene
    Èĺ¸À¯ÀüÀÚ
  • duplicate gene
    º¹»çÀ¯ÀüÀÚ
  • determinant gene
    °áÁ¤À¯ÀüÀÚ
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ
  • gene
    À¯ÀüÀÚ
  • gene amplification
    À¯ÀüÀÚÁõÆø
  • gene analysis
    À¯ÀüÀںм®
  • gene cloning
    À¯ÀüÀÚŬ·Î´×, À¯ÀüÀÚº¹Á¦
  • gene conversion
    À¯ÀüÀÚÀüȯ
  • gene defect
    À¯ÀüÀÚ°á¼Õ
  • gene deletion
    À¯ÀüÀÚ°á¼Õ
  • gene dosage compensation
    À¯ÀüÀÚ¿ë·®º¸»ó
  • gene expression
    À¯ÀüÀÚ¹ßÇö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complementary gene
    º¸Á·À¯ÀüÀÚ, »óÈ£º¸ÃæÀ¯ÀüÀÚ
  • control gene
    Á¦¾îÀ¯ÀüÀÚ
  • cooperating gene
    Çùµ¿À¯ÀüÀÚ
  • gene cloning
    À¯ÀüÀÚŬ·Î´×
  • gene conversion
    À¯ÀüÀÚº¯È¯
  • determinant gene
    °áÁ¤À¯ÀüÀÚ
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ
  • duplicate gene
    º¹»çÀ¯ÀüÀÚ
  • gene defect
    À¯ÀüÀÚ°á¼Õ
  • gene deletion
    À¯ÀüÀÚ°á¼Õ
  • gene expression
    À¯ÀüÀÚ¹ßÇö
  • gene frequency
    À¯ÀüÀÚºóµµ
  • gene
    À¯ÀüÀÚ
  • gene genetics
    À¯ÀüÀÚÀ¯ÀüÇÐ
  • gene imbalance
    À¯ÀüÀÚºÒÆòÇü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Src gene
    Src À¯Àü(ÀÎ)ÀÚ
  • T cell receptor gene
    T¼¼Æ÷[Ç׿ø]¼ö¿ëü À¯ÀüÀÚ
  • additive gene
    »ó°¡À¯ÀüÀÚ(ßÓÊ¥ë¶îîí­).
  • aniridia,pax-6 gene
    PAX-6 À¯ÀüÀÚ(¡­ë¶îîí­)
  • apc gene
    APC À¯ÀüÀÚ(¡­ë¶îîí­)
  • gene
    À¯ÀüÀÚ(ë¶îîí­)
  • gene
    À¯ÀüÀÚ
  • gene amplification
    À¯ÀüÀÚÁõÆø
  • gene amplification
    À¯ÀüÀÚ ÁõÆø
  • gene analyses
    À¯ÀüÀںм®
  • gene analysis
    À¯ÀüÀںм®(¡­ÝÂà°).
  • gene analysis
    À¯ÀüÀںм®.
  • gene cloning
    À¯ÀüÀÚŬ·Î´×
  • gene conversion
    À¯ÀüÀÚº¯È¯.
  • gene conversion
    À¯ÀüÀÚº¯È¯(ܨüµ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lethal mutation
    Ä¡»çµ¹¿¬º¯ÀÌ(¡­ÔÍæ×ܨì¶).
  • lethal mutation
    Ä¡»ç µ¹¿¬º¯ÀÌ
  • lethal titer test
    Ä¡»çÀû Á¤·®½ÃÇè
  • lethal toxin
    Ä¡»çµ¶¼Ò(¡­Ô¸áÈ).
  • lethal toxin
    Ä¡»çµ¶¼Ò(ÊÙËÄËÛ).
  • mean lethal dose =LD50
    50% Ä¡»ç·® (¡­öÈÞÝåÖ).
  • mean lethal dose, Do
    Æò±ÕÄ¡»ç¼±·®
  • median lethal dose =LD50
    50% Ä¡»ç·®(¡­öÈÞÝåÖ), Æò±ÕÄ¡»ç·®.
  • median lethal dose, MLD
    Áß¾ÓÄ¡»ç¼±·®
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá´öÈÞÝåÖ).
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®(̧ËÛ̬Ë×Ëâ).
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝåÖ).
  • minimum lethal dose (MLD)
    ÃÖ¼ÒÄ¡»ç·®
  • mutant, conditional lethal
    Á¶°ÇÄ¡»ç µ¹¿¬º¯ÀÌÁÖ
  • potentially lethal damage repair
    ÀáÀçÄ¡»ç¼Õ»óȸº¹
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • controlling gene
    Á¶Àý À¯ÀüÀÚ(ðàï½ë¶îîí­)
  • c-src gene
    c-src À¯ÀüÀÚ(ë¶îîí­)
  • cytoplasmic gene
    ¼¼Æ÷Áú À¯ÀüÀÚ(á¬øàòõë¶îîí­)
  • D gene
    D À¯ÀüÀÚ(ë¶îîí­)
  • dispensable gene
    ºñÇʼö À¯ÀüÀÚ(Þªù±âÎë¶îîí­) (ÔÒ) nonessential gene
  • diversity gene
    ´Ù¾ç¼º À¯ÀüÀÚ(ÒýåÆàõë¶îîí­) = D gene
  • dominant gene
    ¿ì¼º À¯ÀüÀÚ(éÐàõë¶îîí­)
  • duplicate gene
    º¹»ç À¯ÀüÀÚ(ÜÜÞÐë¶îîí­)
  • early gene
    Á¶±â À¯ÀüÀÚ (ðÄÑ¢ë¶îîí­)
  • epistatic gene
    ¿ìÀ§ À¯ÀüÀÚ (éÐêÈë¶îîí­)
  • essential gene
    Çʼö À¯ÀüÀÚ (ù±âÎë¶îîí­)
  • fused gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
  • fusion gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
  • gene
    À¯ÀüÀÚ(ë¶îîí­)
  • gene activation
    À¯ÀüÀÚ È°¼ºÈ­(ë¶îîí­üÀàõûù)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MLC   1) Minimal Lethal Concentration
  2) Mixed Lymphocyte Culture
PLD POtentially Lethal Damage
SLD Sub-Lethal Damage
CELO chick embryonal lethal orphan [virus]
DL danger list; De Lee [catheter]; deep lobe; developmental level; difference limen; diffusion lung [ca...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LMG Lethal mid-line granuloma
LT Lethal toxin
Ay Lethal yellow
MSL Male-Specific Lethal
MLD Median lethal doses
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • duplicate gene
    Áߺ¹ À¯Àü ÀÎÀÚ
  • exaggeration gene
    °­Á¶ À¯ÀüÀÚ
  • fcc gene
    FCC À¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ ÀûÇÕ À¯ÀüÀÚ, Á¶Á÷ ÀûÇÕ¼º À¯ÀüÀÚ
    ÀÌ½ÄµÈ Á¶Á÷À» ÀÚ±â Á¶Á÷ ¶Ç´Â ¿ÜºÎ Á¶Á÷À¸·Î ÀνÄÇÏ´Â À¯ÀüÀÚ.
  • Is gene
    Is À¯ÀüÀÚ
  • marker gene
    Ç¥Áö À¯ÀüÀÚ
  • multiple drug resistance gene
    º¹ÇÕ ¾àÁ¦ ³»¼º À¯ÀüÀÚ
  • mutable gene
    À̺¯ À¯ÀüÀÚ
  • mutator gene
    º¯ÀÌ À¯¹ß À¯ÀüÀÚ
  • nucleolar gene
    ÇÙ ¼Òü À¯ÀüÀÚ
  • operator gene
    ÀÛµ¿ À¯ÀüÀÚ
  • recessive gene
    ¿­¼º À¯ÀüÀÚ
    ¿­¼º ÈÄÅð ¶Ç´Â ÇÔ¿äÇϱ⠽¬¿î °Í. Áö¹è·ÂÀ» ³ªÅ¸³»Áö ¸øÇϰųª ¿µÇâ·ÂÀ» ÅëÁ¦ÇÏÁö ¸øÇÏ´Â °Í. À¯ÀüÇп¡¼­´Â ´ë¸³ À¯ÀüÀÚ°¡ »óµ¿ ¿°»öü »ó¿¡ ¾øÀ¸¸é ÇüÁúÀ» ¹ßÇöÇÏÁö ¸øÇÏ´Â °Í.
  • regulator gene
    Á¶Àý À¯ÀüÀÚ
  • regulatory gene
    Á¶Àý À¯ÀüÀÚ
  • structural gene
    ±¸Á¶ À¯ÀüÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
lethal dose 50 <pharmacology> The amount, or dosage, of a toxin necessary to kill 50% of the experimental subjects.
(16 Mar 1998)
lethal dwarfism Dwarfism leading to intrauterine or neonatal death.
(05 Mar 2000)
lethal equivalent A combination of selective effects that on average have the same impact on the composition of the gene pool as one death; e.g., two carriers at 50% risk of dying would be the lethal equivalent of one carrier at 100% risk, in the population genetics of recessive traits lethal equivalent is expressed as twice the sum of the expected number of deaths ascribable to the genetic load.
Expression used of the genetic load of recessive genes in heterozygous state that if in homozygous state would cause death or carry a risk of death. The expected number of deaths from all such genes is expressed in lethal equivalent.
(05 Mar 2000)
lethal factor A disorder that prevents effective reproduction by those affected; e.g., Klinefelter syndrome.
(05 Mar 2000)
lethal midline granuloma Destruction of the nasal septum, hard palate, lateral nasal walls, paranasal sinuses, skin of the face, orbit and nasopharynx by an inflammatory infiltrate with atypical lymphocytic and histiocytic cells; presumably a form of lymphoma in most cases.
An obsolete term for polymorphic reticulosis.
Synonym: granuloma gangrenescens, malignant granuloma, midline malignant reticulosis granuloma.
(05 Mar 2000)
lethal mutation <genetics, molecular biology> Mutation that eventually results in the death of an organism carrying the mutation.
(18 Nov 1997)
allelic gene See: allele, dominance of traits.
(05 Mar 2000)
antibiotic resistance gene Genes in a microorganism which confer resistance to antibiotics, for example by coding for enzymes which destroy it, by coding for surface proteins which prevent it from entering the microorganism, or by being a mutant form of the antibiotic's target so that it can ignore it.
(09 Oct 1997)
autosomal gene A gene located on any chromosome other than the sex chromosomes (X or Y).
(05 Mar 2000)
bicoid gene A group of genes which are important to the proper development of the head and thorax in the embryo of the fruit fly Drosophila melanogaster.
(09 Oct 1997)
BRCA1 breast cancer susceptibility gene This mutated (changed) version of the BRCA1 gene makes a person susceptible to developing breast cancer.
(12 Dec 1998)
calcitonin gene-related peptide <protein> A second product transcribed from the calcitonin gene. Calcitonin gene related peptide is found in a number of tissues including nervous tissue. It is a vasodilator that may participate in the cutaneous triple response.
It is a neuropeptide of 37 amino acids with structural homology to salmon calcitonin. Co-localises with substance P in neurons. It occurs as a result of alternative processing of mRNA from the calcitonin gene.
The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.
Intracerebral administration leads to a rise in noradrenergic sympathetic outflow, a rise in blood pressure and a fall in gastric secretion.
Acronym: CGRP
(05 May 2002)
cancer susceptibility gene tumour suppressor gene
rab gene 1. <molecular biology> One of the three main groups of ras like genes specifying small GTP-binding proteins (the others are ras and rho). Rab proteins are involved in vesicular traffic and seem to control translocation from donor to acceptor membranes.
2. <cell biology> Gene family in plants responsive to abscisic acid: encode proteins of 15-17 kD.
(18 Nov 1997)
pair rule gene <molecular biology> A segmentation gene, expressed sequentially between gap genes and segment polarity genes. In development of Drosophila, a set of about 8 genes that are expressed only in alternate segments (odd or even) of the developing embryo. Loss of function mutants thus lack alternate segments.
Examples: even skipped (eve), fushi tarazu (ftz), hairy.
(18 Nov 1997)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
lethal gene A gene that results in death. Lethal genes can be either dominant or recessive. Posted on April 23, 2005, 18:12, Last updated on December 4-, 2005, 23: 1 |
Ãâó: ratguide.com/breeding/genetic_terms.php
lethal gene A gene which causes the death of the calf, usually before or at birth. Most gene pairs causing inherited lethals must be in the homozygous (pure) condition to be fatal to the calf. By this definition the gene that causes the short-legged Dexter is a lethal gene, but in it
Ãâó: bellefourchedexters.tripod.com/Articles/Genetic%20...
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • recessive gene
    ¿­¼º À¯ÀüÀÚ
  • regulator(regulatory) gene
    Á¶Àý(Á¦¾î)À¯ÀüÀÚ
  • restorer gene
    ȸº¹ À¯ÀüÀÚ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á